<DOC>
	<DOCNO>NCT01623336</DOCNO>
	<brief_summary>The purpose study demonstrate noninferiority BIP48 ( 48 kDa peginterferon alfa-2b ) compare Pegasys ® ( 40 kDa peginterferon alfa-2a ) associate ribavirin , naive patient chronic hepatitis C .</brief_summary>
	<brief_title>BIP48 ( Peginterferon Alfa 2b 48kDa ) Compared With Pegasys® ( Peginterferon 2a 40kDa ) Treatment Chronic Hepatitis C</brief_title>
	<detailed_description>The study open , multicenter , randomize , control phase II - III trial . Patients ( n = 740 ) randomize ( 1:1 ) receive BIP48 ( peginterferon alfa-2b 48kDa ) Pegasys ® ( peginterferon alfa-2a 40kDa ) 180 microgram , subcutaneously , week , associate ribavirin dose 1000-1250 mg , orally , daily . For genotype 1 treatment time 48 72 week genotypes 2 3 , 24 48 week . The study 's population naive patient , sex , 18 70 year old , chronic hepatitis C ( HCV ) , genotypes 1 , 2 3 , 18 25 Brazilian research center . Diagnostic criterion follow : positive anti-HCV qualitative PCR , liver biopsy show degree fibrosis least mild inflammatory activity , perform last 24 month . The interruption Criteria : partial virological response 12 week positive quantitative PCR week 24.The primary outcome rate sustain virologic response secondary endpoint quality life treatment , frequency adverse event cost-effectiveness . As substudy , perform comparative assessment 24 patient , evaluate viral kinetics , pharmacokinetics pharmacodynamics repeat dos alfapeginterferons .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>1. antiHCV positive ; 2. viral load HCV positive ; 3. viral genotype 1 , 2 3 ; 4. absence previous treatment chronic hepatitis C ; 5. liver biopsy perform last 36 month classify Metavir score least A1 , degree fibrosis ; 6. age 18 70 year old ; 7. hemoglobin great 11 g / dl ; 8. platelet count high 75.000/mm3 ; 9. neutrophil high 1.500/mm3 ; 10. use , least two contraceptive method treatment 36 week last dose study medication ( male female subject fertile age ) ; 11. concordance signing informed consent . 1. decompensated cirrhosis ( ChildPugh score &gt; 6 ) ; 2. history bleed gastroesophageal varix ; 3. hemoglobinopathy ; 4. hepatocellular carcinoma ; 5. coinfection HIV HBV ; 6. coexist chronic liver disease , autoimmune hepatitis , Wilson disease , hemochromatosis , chronic obstructive cholestatic disease autoimmune disease , alcoholic liver disease ; 7. malignancy except basal cell carcinoma situ cervix carcinoma ; 8. systemic autoimmune disease , except compensate autoimmune thyroid diseases ; 9. uncontrolled seizure ; 10. primary immunodeficiency ; 11. myelosuppression ; 12. coagulation disorder ; 13. thrombophilias ; 14. thrombopathy ; 15. decompensated heart failure ; 16. chronic renal failure ; 17. diagnosis comorbidity would compromise subject 's participation research study judge investigator ( eg , neuropsychiatric disease , systemic infection antibiotic use within 4 week , decompensated diabetes mellitus , ischemic heart disease , heart failure , respiratory renal uncontrolled hypertension ) ; 18. prior organ transplantation , except cornea ; 19. alcohol consumption exceed 20g/day woman 40g/dia men past six month ; 20. use illicit drug previous six month ; 21. use immunosuppressive agent previous six month ; 22. pregnancy lactation ; 23. male research subject whose sexual partner pregnant ; 24. previous treatment IFN ribavirin last 6 month prior inclusion ; 25. subject hypersensibility IFN alpha / component ; 26. subject hypersensibility ribavirin / ingredient ; 27. participation another clinical study last 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>HEPATITIS</keyword>
	<keyword>HEPATITIS C</keyword>
	<keyword>PEGINTERFERON</keyword>
	<keyword>BIOEQUIVALENCE</keyword>
	<keyword>TREATMENT</keyword>
</DOC>